IL-13RA2, or Interleukin 13 Receptor Alpha 2, is a protein that has gained significant attention for its role in cancer and as a potential therapeutic target. IL-13RA2 is overexpressed in various cancers, including melanoma, renal cell carcinoma, adrenocortical carcinoma, and several brain tumors. Its expression is associated with tumor invasion, metastasis, and poor prognosis. Unlike the IL-13Rα1, which activates the JAK/STAT pathway, IL-13RA2 was considered a non-signaling receptor due to its short intracellular domain. However, it has been shown to participate in signaling pathways that promote tumor progression, such as those involving AP-1 and ERK.